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Highlights  
 ON AVERAGE CD4(CELLS/MM3) INCREASED FROM 391 TO 523 AFTER 12 MONTHS OF 
ART  
 RATE OF CD4 INCREASE WAS HIGHER AMONG WOMEN WITH LOWER BASELINE CD4 
COUNT. 
 STARTING ART AT CD4 >500 WAS POSITIVELY ASSOCIATED WITH CD4 NORMALIZATION  
 NO DIFFERENTIAL RISK OF HIV-RELATED CLINICAL EVENTS BY BASELINE CD4 LEVELS   
 
 
 
Abstract  
Objective: To compare health outcome following initiation of antiretroviral therapy (ART) for 
asymptomatic HIV-infected pregnant women at different CD4 levels.  
Methods: We analyzed data from 706 asymptomatic HIV-infected Ethiopian women initiating 
ART during pregnancy between February 2012 and October 2016. The outcomes evaluated were 
CD4 gain, CD4 normalization (CD4 count ≥750cells/mm3) and occurrence of HIV-related 
clinical events after twelve months of treatment.   
Result: On average, CD4 count (cells/mm3) increased from 391(95% CI: 372-409) at baseline to 
523(95% CI: 495-551) after twelve months of treatment. Rate of CD4 gain was higher among 
women with baseline CD4 between 350 and 499 compared to CD4 >500 (207 versus 6, p < 
0.001). But women with baseline CD4 between 350 and 499 could not catch up with those with 
CD4 >500. Women with baseline CD4 >500 had significantly higher likelihood of achieving 
CD4 normalization as compared to those with CD4 between 350 and 499 (AOR = 0.32, 95% CI: 
0.13-0.76). No strong evidence of differential risk in the occurrence of HIV-related clinical 
events.  
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Conclusion: Starting ART for asymptomatic HIV-infected women with CD4 count 
>500cells/mm3 was beneficial to preserve or recover immunity after 12 months of treatment in a 
resource limited setting.  
 
Keywords: HIV, Antiretroviral drugs, ART, clinical outcome 
 
Introduction  
Antiretroviral therapy (ART) is effective in reducing mortality (1), preventing mother-to-child 
transmission (MTCT) (2, 3), and sexual transmission of HIV (4).  However, the optimal time to 
start treatment has been a topic of debate (5), as a result, HIV treatment guidelines have been 
regularly revised to balance risks and benefits of treatment. Initiation of ART immediately after 
diagnosis is currently recommended (5-7) following reports of clinical trials demonstrating the 
benefit of starting ART as early as possible (8-11).   
 
The effectiveness of ART in actual clinical settings might be inferior to what is reported by 
clinical trials, because clinical trial participants are more likely to be adherent to treatment than 
those treated in actual program settings. The benefit of early ART might even be very minimal 
among young asymptomatic adults with high level of CD4 count, as they have poor treatment 
adherence and retention (12-14), that could increase drug resistance (15), and impact the 
potential benefit of early ART (14). In fact, a sub-group analysis of a clinical trial among adults 
aged below 30 years with CD4 count above 500cells/mm3 showed that those initiated treatment 
and those deferred treatment have similar rate of disease progression in the first 18 months (16). 
This finding demonstrates that the benefit of early ART is not uniform across various patient 
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groups. Therefore, observational studies are essential to clarify concerns of early initiation of 
ART. There are also reports indicating a greater risk of adverse outcomes (17, 18), associated 
with early ART initiation. Although newest antiretroviral drugs are more tolerable and have 
fewer side effects, they are not commonly used in low income settings. 
 
The burden of HIV/AIDS in Ethiopia is substantial. It is estimated that 665,116 (1.1%) adults 
were living with the virus in 2016 and the majority (61.5%) were women (19). At the time of the 
study, indication to start ART for adults in Ethiopia was based on CD4 count or disease 
progression. However, pregnant women were started on ART up on diagnosis, to prevent 
mother-to-child transmission (20). The CD4 count threshold for initiating treatment for 
asymptomatic adults was 350 cells/mm3, but was subsequently increased to 500 cells/mm3 in 
2013, and ART was recommended for all HIV infected adults in 2017 (21). The recommended 
type of ART has also been regularly revised; at the time of the study, a combination of tenofovir, 
lamivudine and efavirenz (TDF-3TC-EFV) was the preferred first line ART. Prophylaxes 
including co-trimoxazole and isoniazid preventive therapy have been routinely provided to 
prevent opportunistic infections. Treatment response was monitored by CD4 count measured 
every six months (21). Evaluating the health benefits of ART for HIV-infected but asymptomatic 
Ethiopian women with high level of CD4 counts is important. To our knowledge, there are no 
previous Ethiopian studies addressing these questions. Therefore, the main objective of our study 
was to evaluate the clinical and immunological outcomes of asymptomatic HIV-infected 
pregnant women who initiated ART at different CD4 levels in Ethiopia.  
 
Materials and Methods  
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Study population 
The study was conducted in three hospitals and six health centers in Addis Ababa, Ethiopia. 
Information was obtained from clinical charts and ART databases of HIV-infected pregnant 
women attending prenatal care follow-up between February 2012 and October 2016.  The 
clinical charts of 926 HIV-infected women who initiated ART during pregnancy were reviewed. 
We excluded HIV-infected pregnant women who had missing information about the type or 
timing of ART initiation, baseline CD4 count and WHO stage at the time of ART initiation. 
Women with HIV related clinical symptoms at the time of ART initiation, and those who did not 
return after HIV diagnoses were also excluded from the analysis. This left 706 HIV-infected 
asymptomatic pregnant women eligible for analysis of prospective HIV-related clinical events. 
Follow-up CD4 measurement was available for 668 women after six months and 297 women 
after twelve months of ART initiation (Figure 1). This historical chart review was regarded as 
clinical practice and outcome assessment and therefore did not require written consent. The study 
was approved by the Norway Regional Committees of Medical and Health Research Ethics of 
South/East Norway, Jimma University Ethical Review Board, and Addis Ababa City 
Administration Health Bureau.  
 
Exposure variables  
The main exposure variable was baseline CD4 count, which was measured at the time of ART 
initiation. Baseline CD4 count was categorized as less than 350 cells/mm3, between 350 and 499 
cell/mm3 and 500 cells/mm3 or more. We also evaluated the role of the type of ART regimen. 
According to the Ethiopian treatment guideline, the first drug of choice was a combination of 
tenofovir, lamivudine and efavirenz (TDF-3TC-EFV). Alternatives include a combination of 
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tenofovir, lamivudine and nevirapine (TDF-3TC-NVP), zidovudine, lamivudine and nevirapine 
(ZDV-3TC-NVP) and zidovudine, lamivudine and efavirenz (ZDV-3TC-EFV). We categorized 
the type of ART as TDF-3TC-EFV compared to all other ART types (TDF-3TC-NVP, ZDV-
3TC-NVP and ZDV-3TC-EFV).   
 
Outcomes 
The outcomes evaluated were average CD4 gain, CD4 normalization and incidence of HIV-
related clinical events after twelve months of treatment. To define CD4 normalization, different 
studies used different cutoff points, ranging from 500 to 900 cells/mm3(22-24).  Two Ethiopian 
studies reported 723 and 775 cells/mm3 as median CD4 counts of HIV-free healthy Ethiopian 
adults (25, 26). We therefore defined CD4 normalization as achieving CD4 counts of at least 
750cells/mm3.  The WHO clinical staging categorizes HIV infection into four stages (stage I-IV), 
stage one indicates that the patient has no HIV-related clinical symptoms or mild symptoms, and 
stage four indicates severe form of HIV-related illnesses including malignancies (27). Long-term 
outcomes, such as AIDS-defining illnesses and death were rare, in part due to the short follow-up 
period.  As a result, occurrences of any WHO stage II-IV clinical events during our follow-up 
period were combined for the analysis. 
 
Covariates  
Additional information was gathered on maternal background characteristics likely to be 
associated with maternal immunologic and clinical outcomes. These included age, gestational 
week, level of education (no education, primary, secondary and tertiary), marital status (married 
and other), and weight in kilogram at the time of treatment initiation. We also gathered 
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information on hemoglobin level (mg/dl) at the time of treatment initiation and self-reported 
adherence to treatment (missing less than 5% of the prescribed pills, categorized as “good”, 
missing between 5 to 20% “fair” and missing more than 20% “poor”).  
 
 
Statistical analysis  
We compared background characteristic of women by baseline CD4 category using chi-square 
for categorical covariates or Wilcoxon rank-sum test for continuous covariates. We used linear 
regression to examine the associations of baseline CD4 level and types of ART initiated with 
change in CD4 count at six and twelve months, reporting mean difference and 95% confidence 
intervals (CIs). We ran logistic regression to evaluate associations of baseline CD4 count and 
type of ART regimen with the probability of CD4 normalization, reporting odds ratios (ORs) and 
95% CIs. Cox-proportional hazard regression model was used to evaluate associations of 
baseline CD4 level and type of ART regimen with incident HIV-related clinical events, reporting 
hazard ratios (HRs) and 95% CIs. We censored follow-up time for each woman at the first 
registration of a WHO stage II to stage IV HIV-related clinical events, at the last visit before 
treatment interruption for more than 3 months, or at twelve months (end of follow-up). The 
multivariable analyses were adjusted for known covariates including age, gestational age, 
weight, marital status, education, hemoglobin level and adherence to treatment. In addition, 
baseline CD4 count and type of ART were adjusted for each other. Covariates were categorized 
as indicated in table 1 and entered using dummy variables.  Most of the covariates had some 
missing values (ranging from 31% for level of education to 2% adherence to treatment). We 
therefore imputed missing values of covariates using chained equations, imputing a total of 20 
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datasets. The imputation model included all exposures, covariates, and outcome variables. We 
observed similar results in the multiple imputation and complete-case analyses. We report the 
results based on the imputed data as main results, while the findings from the complete-case 
analysis are presented in the supplement. The analyses were conducted using STATA version 13 
(Stata Corp., College Station, TX). 
  
Result  
A total of 706 HIV-infected asymptomatic (WHO Stage I) women initiating ART during 
pregnancy were included in the analysis of occurrence of HIV-related clinical events. 
Background characteristics of women included (n=706) and excluded (n=220) from the analysis 
were largely similar, except that excluded women were younger and less compliant to treatment 
(Supplemental table 1). Median age at ART initiation was 28 years (IQR: 25-30) and median 
gestational week at initiation was 20 weeks (IQR: 15-27). The majority of women (80.5%) 
initiated TDF-3TC-EFV. Women with baseline CD4 count ≥500cells/mm3 were younger and had 
higher hemoglobin level than women with CD4 below 500 cells/mm3.  The distributions of other 
background characteristics were largely similar across baseline CD4 levels (Table 1). The 
distribution of background characteristics of the subsample of women included in the evaluation 
of CD4 recovery at 6 months (n=668) and 12 months (n=297) after treatment initiation is 
presented in supplemental table 2. 
 
CD4 count recovery  
On average, CD4 count increased from 391 (95% CI: 372-409) cells/mm3 at the time of ART 
initiation, to 497 (95% CI: 478- 515) cells/mm3 after six months, and to 523 (95% CI: 495-551) 
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cells/mm3 after twelve months. We observed a decrease in the CD4 count in 20% of the women 
after six months and 18% of the women after twelve months. The median CD4 count measured 
during follow-up according to baseline CD4 category and type of ART is shown in figures 2 and 
3. The average CD4 gains after twelve months were 175 cells/mm3 (SD = 187) among women 
with baseline CD4 below 350 cells/mm3, 207 cells/mm3 (SD = 162) among women with baseline 
CD4 between 350 and 499 cells/mm3, and 6 cells/mm3 (SD = 211) among women with baseline 
CD4 of 500 cells/mm3 or more (p < 0.001). On average, CD4 count after twelve months reached 
390, 624, and 698 cells/mm3 for women with baseline CD4 counts below 350, 350 to 499 and 
500 cells/mm3 or more respectively. After twelve months of treatment, a CD4 count of above 
500 cells/mm3 was achieved by 22%, 75% and 82% of women with baseline CD4 below 350, 
350 to 499 and 500cells/mm3 or more respectively.   
 
We also evaluated CD4 normalization, which was defined as reaching CD4 count of 750 
cells/mm3 or more. CD4 normalization was achieved by 18% of women after twelve months. As 
compared to those with baseline CD4 count less than 500 cells/mm3, a higher proportion of 
women with baseline CD4 count of 500 cells/mm3 or more achieved CD4 normalization after 
twelve months, as compared to the rest of women (43.6% versus 8.6%, p<0.001).   
 
In adjusted regression analysis, treatment initiation at low level of CD4 count was associated 
with higher CD4 gains during follow-up. For example, compared to women with baseline CD4 
count of 500 cells/mm3 or more, those with baseline CD4 count between 350 and 499 cells/mm3 
had a larger CD4 gain after six (adjusted mean difference = 142 cells/mm3, 95% CI: 101, 183) 
and twelve months (adjusted mean difference = 207 cells/mm3, 95% CI: 140, 275) (Table 2). 
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Compared to TDF-3TC-EFV, women who initiated other types of ARTs had lower CD4 gains 
after twelve months (adjusted mean difference = -80 cells/mm3, 95% CI: -140, -21) (Table 2).  
 
After adjusting for relevant covariates, we found that higher baseline CD4 count was positively 
associated with CD4 normalization following ART in these asymptomatic women. Compared to 
women with CD4 count of 500 cells/mm3 or more at treatment initiation, a lower proportion of 
women with baseline CD4 count between 351 and 499 cells/mm3 achieved CD4 normalization 
after six (adjusted OR = 0.10, 95% CI: 0.04- 0.24) and twelve months (adjusted OR = 0.32, 95% 
CI: 0.13 -0.76) (Table 3). We observed no strong evidence that the likelihood of CD4 
normalization differed according to type of ART regimen (Table 3).  
 
Clinical outcomes  
A total of 706 pregnant women who contributed 682 person-years of follow-up were included in 
the analysis of clinical events. A total of 54 women were censored because treatment was 
interrupted for 3 or more months and one woman was censored after having died.  During the 
follow-up, 24 women experienced HIV-related clinical events. Of these, 20 (2.9%) were WHO 
stage II, three (0.5%) were WHO stage III and one (0.2%) was WHO stage IV. Incidence rate of 
HIV-related clinical events was 3.5 per 100 person-years of follow-up (95% CI: 2.4-5.2 per 100 
person-years). Incidence of HIV related event was 5.3 per 100 person-years, among women with 
baseline CD4 count below 350 cells/mm3;  2.2 per 100 person-years among women with baseline 
CD4 count between 351 and 499 cells/mm3; and  1.1 per 100 person-years among women with 
CD4 count 500 cells/mm3 (p= 0.01).  
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In adjusted analysis, the incidence of HIV related clinical events among women with baseline 
CD4 of 500 cells/mm3 or more was not significantly different from women with a baseline CD4 
count between 350 and 499 cells/mm3 (adjusted HR = 2.01, 95% CI: 0.35-12.55), or from 
women with a baseline CD4 count of less than 350 cells/mm3 (adjusted HR = 4.10, 95%CI: 0.91-
18.47) (Table 3). Similarly, the association between type of ART and incidence of clinical events 
observed in unadjusted analysis was attenuated in adjusted analysis (Table 5).  
 
Discussion  
Our findings indicated that starting ART for asymptomatic HIV-infected pregnant women before 
their CD4 count falls below 500 cells/mm3 is beneficial for CD4 normalization (CD4 recovery to 
750 cells/mm3 or more) in resource-limited settings. Women who started ART at  lower baseline 
CD4 count (<500 cells/mm3) could not catch up with those who had higher baseline CD4 count 
(≥500 cells/mm3) after twelve months of treatment although the rate of CD4 gain was faster 
among women initiating ART at lower baseline CD4 count. It is well known that having a CD4 
count within the normal range among HIV infected individuals is associated with lower risk of 
HIV-related illnesses (23, 28) and a greater life expectancy (29).  
 
Although the benefit of early initiation of ART has been demonstrated by clinical trials (9, 10), 
the benefit was not uniform across various patient groups. In addition, it is not certain that the 
observed effectiveness in clinical trials can be replicated in different real program settings in low 
income settings. Moreover, the type of ART regimen used in clinical trials was not common in 
low income settings which make generalization of the findings to these settings problematic. 
Therefore, observational studies demonstrating the benefit of early ART in real clinical settings 
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is necessary.  Our study showed that early initiating ART may be beneficial in preserving or 
recovering immunity in resource limited settings. The finding ease the concerns that early ART 
may not be effective for asymptomatic adults with high level CD4 count and supports the recent 
recommendations of early initiation of ART for all HIV-infected individuals by the WHO and 
the Ethiopian government (5, 30). Previous studies also reported that initiating ART when the 
CD4 count is >500 cells/mm3 compared to deferring treatment until the CD4 drops below 500 
cells/mm3 significantly increase the likelihood of CD4 normalization (22, 24, 31). The benefit of 
early initiation of treatment is further reinforced by previous findings which showed that early 
initiation of ART preserves immune function (23).  
  
On average CD4 count increased across all baselines CD4 categories during follow-up. 
However, the rate of CD4 count increase during follow-up was higher among women who 
initiated ART at a lower baseline CD4 count. The finding is not unexpected as most women who 
initiated treatment at higher baseline CD4 count already have normal or near normal CD4 count, 
and are therefore not expected to have large CD4 gains during follow-up. The likely CD4 count 
trajectory without treatment is a progressive decline after a transient increase during the acute 
HIV infection phase (23). Preventing CD4 count decline is the likely benefit of treatment among 
women who have high baseline CD4 count. Previous studies reported inconsistent findings. 
Some studies reported a larger CD4 increase among patients with lower baseline CD4 count (32, 
33), and others demonstrated a similar rate of CD4 increase despite the difference in baseline 
CD4 count (34, 35).  
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Our study could not determine the long term change in CD4 count, as the follow-up time was 
only twelve months. Findings from a few previous studies evaluating CD4 trajectories over time 
demonstrated that the CD4 counts continued to increase up to 3 to 4 years after initiation of ART 
before reaching a plateau after 4 to 5 years in all CD4 categories (24, 32). Other studies indicated 
that the CD4 counts continue to increase for 7 years among those who initiated treatment at CD4 
count less than 350 cells/mm3 (22, 33). However, these studies did not evaluate the effect of 
treatment initiation at different CD4 levels among asymptomatic HIV-infected individuals.  
 
We also evaluated clinical outcomes according to baseline CD4 count. Outcomes, such as AIDS 
defining illnesses and mortality during follow up period were very rare due to the short follow-
up time. As a result, we considered WHO stage II-IV HIV-related clinical events in combination. 
The study demonstrated some evidence of lower risk of HIV-related clinical events, among 
women who initiated ART at baseline CD4 count of 500cells/mm3 as compared to women who 
initiated treatment with a CD4 count below 500 cells/mm3, although the confidence intervals 
were wide due to the small number of events.  
 
The “90-90-90 treatment target” which aims at diagnosing 90% of HIV-infected individuals, 
treating  90%  of those diagnosed and achieve viral suppression for 90% of treated individuals, is 
a key strategy to achieve one of the sustainable development goals (SDG) of ending AIDS as a 
public health threat by 2030  (36).  However, low level of treatment adherence, lost to follow-up, 
and drug resistance needs to be addressed to achieve the SDG goals. ART should be taken for 
life with adequate level of adherence to get the desired benefit. However, asymptomatic 
individuals with a high level of CD4 count might have poor adherence and less motivated to 
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continue treatment (12). For example, a study in Malawi reported that 73% of women continued 
ART treatment three months after initiation but only 56% were adherent to treatment (37). Drug 
resistance is another problem that should be taken into account. The 2017 WHO HIV drug 
resistance report showed that the level of HIV drug resistance among the first line drugs used in 
most low and middle income countries was very high; three of the four sub-Saharan African 
countries included in the report had greater than 10% pretreatment resistance for non-nucleoside 
reverse transcriptase inhibitors (NNRTIs) (ranging from  8.1% to 15.4%) (38). Mathematical 
modeling estimates showed that if NNRTI pretreatment resistance exceeds 10%, and NNRTI-
based ART continue to be a first-line treatment in the next 15 years, NNRTI pretreatment 
resistance could become responsible for 16% of AIDS deaths (n = 890 000) and 9% of new HIV 
infections (n = 450 000) in sub-Saharan Africa alone (39). Notably, early initiation of treatment 
is found to reduce the risk of HIV drug resistance compared to delaying treatment (40, 41).  
 
Our findings should be understood in the light of the following limitations. Because of the 
observational nature of the study, different confounding factors could bias findings; but we were 
able to adjust for a broad range of known potential confounders. We also explore influence 
calendar year at the start of ART but we found no association between calendar year at the start 
of ART and treatment outcome. The study was conducted in resource limited urban settings 
which might limit its generalizability to other settings. Moreover, our study was limited by 
exclusion of substantial number of women due to missing information, although our comparison 
of characteristics of those excluded and those included showed that the two groups were very 
similar. More women with lower CD4 counts were started on other types ART. This is because 
of evolution of the treatment guideline. Before 2013, efavirenz was not recommended during 
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early pregnancy for fear of side effects; meanwhile eligibility for ART was based on CD4 count 
(< 350 cell/mm3) or disease progression. Viral load and CD4 to CD8 ratio which are important 
clinical indicators of treatment success were not measured. Our study was also limited by short 
follow-up period; as a result we could not evaluate the long term trend of CD4 count and clinical 
outcomes. Notably, previous studies indicate that most of the CD4 gains in patients on ART are 
achieved within one year of treatment (32, 42).  
 
In conclusion, initiation of ART for asymptomatic HIV-infected pregnant women with CD4 
count > 500 cells/mm3 was beneficial to preserve or recover immunity after 12 months of 
treatment in resource limited settings. Our finding supports the recent WHO recommendations of 
universal ART for HIV-infected individuals including pregnant women as early as possible. A 
large-scale study on drug toxicity and drug resistance in resource-limited settings among men 
and women who initiate ART at different CD4 counts is warranted.      
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Figure 1. Flow diagram: health outcomes of asymptomatic HIV infected pregnant Ethiopian 
women initiated ART at different baseline CD4 count.  
Legend: ART: antiretroviral therapy, WHO: World Health Organization  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Women who were asymptomatic 
at ART initiation (n=855)  
 
Had HIV-related clinical symptoms 
at the time of ART initiation (n=52) 
WHO stage at baseline is unknown 
(n=9) 
 
 
706 included in the analysis clinical events,  
668 included in analysis of CD4 after six months,  
297 included in the analysis of CD4 after 12 months 
 
Women who had at least one 
follow-up visits (n=828) 
Women with information on 
type of ART (n=916) 
Baseline CD4 measurement not 
available (n=122) 
 
Information on type of ART 
was unknown (n=10) 
No follow-up visits (n=27) 
Clinical records of women who 
initiated ART during pregnancy 
(n=926) 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IPT
24 
 
 
Figure 2. Median CD4 count during follow-up by baseline CD4 count category in asymptomatic 
HIV infected pregnant women 
Legend: CD4 count measurement was available for 706 women at baseline, 668 after six months 
and 297 at twelve months. Of 706 women, 179 women had baseline CD4 500 cells/mm3 and 
more, 137 women had baseline CD4 350 to 499 cells/mm3 and 352 women had baseline CD4 
less than 350cells/mm3  
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Figure 3. Median CD4 count during follow-up by type of ART regimen initiated in 
asymptomatic HIV infected pregnant women. 
Legend: CD4 count measurement was available for 706 women at baseline, 668 after six months 
and 297 at twelve months. Of these, 569 women at the start of ART, 538 after six months and 
130 after twelve months were on TDF-3TC-EFV. 
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Table 1. Characteristics of 706 HIV infected asymptomatic pregnant Ethiopian women by 
baseline CD4 count category 
Characteristics  Total  Baseline CD4 category  
(n=706)  
 
<350 cells/mm3 
(n=373) 
350-
499cells/mm3 
(n=145) 
>500cells/mm3 
(n=188) 
P-value a 
Age in years (median +IQR) 28(25-30) 28(25-30) 28(25-30) 27(24-30) 0.02b 
Gestational age in weeks at 
ART initiation (Median 
+IQR) 
20(15-27) 21(16-28) 20(15-26) 19(13-26) 0.04b 
Marital status       
Married  659(93) 340(91.2) 137(94.5) 182(96.8) 0.04 
Others  44(6) 31(8.3) 7 (4.8) 6(3.2)  
Unknown  3(0.4) 2(0.5) 1(0.7) 0(0)  
Educational status       
No education 60(9) 26(7.0) 15(10.3) 19(10.1) 0.54 
Primary 188(27) 96(25.7) 40(27.6) 52(27.7)  
Secondary 188(27) 103(27.6) 35(24.1) 50(26.6)  
Higher  51(7) 32(8.6) 7(4.8) 12(6.4)  
Unknown  219(31) 116(8.6) 48(33.1) 55(29.3)  
Baseline weight in kg 
(median +IQR) 
56(50-64) 56(50-62.5) 56(51-62) 56(50-65) 0.87b 
Hemoglobin in mg/dl 
(median +IQR) 
12(11-13) 12(11-13) 12(11-13) 12(12-13) 0.001b 
Adherence to treatment       
Good  612(87) 318(85.3) 130(89.7) 164(87.2) 0.47 
Fair  38(5) 21(5.6) 7(4.8) 10(5.3)  
Poor  42(6) 28(7.5) 6(4.1) 8(4.3)  
Unknown   14(2) 6(1.6) 2(1.4) 6(3.2)  
Types of ART initiated       
TDF-3TC-EFV 569(81) 258(69.2) 137(94.5) 174(92.6) <0.001 
Other ART types c 137(19) 115(29.8) 8(5.5) 14(7.4)  
Data are n(%) or median (IQR). ZDV: Zidovudine, 3TC: lamivudine, NVP: nevirapine, EFV: efavirenz, TDF: 
tenofovir, ART: antiretroviral therapy, IQR: Interquartile range.  
a Statistical tests did not consider missing values. 
b Wilcoxon rank-sum tests, the rest are chi-square test results  
c Other type of ARTs which include: TDF-3TC-NVP,  ZDV-3TC-NVP or ZDV-3TC-EFV 
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Table 2. Association of baseline CD4 count and ART regimen with CD4 count gain from 
baseline to six and twelve months follow-up in asymptomatic HIV infected pregnant 
women. 
Exposure 
variables  
CD4 count gain (cells/mm3) at six months 
(N=668)  
CD4 count gain (cells/mm3) at 12 months (N=297) 
n Mean 
(SD) 
Unadjusted 
β(95%CI) 
Adjusted 
β(95%CI)a 
n Mean 
(SD) 
Unadjusted 
β(95%CI) 
Adjusted 
β(95%CI)a 
Baseline 
CD4 
(cells/mm3 ) 
        
>500  179 -4.5(224) Reference  Reference  78 6(211) Reference  Reference  
350 to 499  137 130(152) 134(97, 172) 142(101, 183) 66 207(162) 201(139, 
264) 
207(140, 275) 
< 350  352 158(141) 162(132, 193) 173(139,208) 153 175(187) 169(118, 
221) 
200(141, 259) 
Type of ART          
TDF-3TC-EFV 538 106(185) Reference  Reference 235 144(210) Reference  Reference 
Other ART 
types* 
130 121(174) 16 (-19, 51) -29(-65, 7) 62 111(178) -33(-90, 24) -80(-140, -21) 
ART: antiretroviral therapy, TDF-3TC-EFV: a combination of tenofovir, lamivudine and efavirenz, 
a The regression analyses were adjusted for age at treatment initiation, gestational age at ART initiation, weight at 
treatment initiation, marital status, level of education, hemoglobin level and treatment adherence. In addition, 
baseline CD4 count and type of ART were adjusted for each other.  
b Other type of ARTs include: ARTs comprised of TDF-3TC-NVP, ZDV-3TC-NVP or ZDV-3TC-EFV 
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Table 3. Association of baseline CD4 count and type of ART regimen with CD4 
normalization (CD4 > 750 cells/mm3) at six and twelve months in asymptomatic HIV 
infected pregnant women. 
Exposures CD4 normalization at six months (n=668) CD4 normalization at 12 months (n=297) 
n/N(%) Unadjusted  
OR  (95%CI) 
Adjusted  
OR(95%CI)a 
n/N(%) Unadjusted  
OR  (95%CI) 
Adjusted  
OR(95%CI)a 
Baseline CD4 
(cells/mm3) 
      
>500  65/179(36) 1 1 34/78(44) 1 1 
350 to 499  8/137(6) 0.11(0.05-
0.24) 
0.10(0.04-0.24) 13/66(20) 0.32(0.15-
0.67) 
0.32(0.13-
0.76) 
< 350  9/352(3) 0.05(0.02-
0.10) 
0.06 (0.03 -
0.13) 
6/153(4) 0.05(0.02-
0.13) 
0.06(0.02-
0.18) 
Type of ART        
TDF-3TC-EFV 78/538(15) 1 1 50/235(21) 1 1 
Other ART 
types* 
4/130(3) 0.19 (0.07-
0.52) 
0.43(0.12-1.63) 3/62(4.8) 0.19 (0.06-
0.63) 
0.48 (0.12-
2.00) 
OR: odds ratio, ART: antiretroviral therapy, TDF-3TC-EFV: a combination of tenofovir, lamivudine and efavirenz, 
a The regression analyses were adjusted for age at ART initiation, gestational age at ART initiation, weight at ART 
initiation, marital status, level of education, hemoglobin level and treatment adherence. In addition, baseline CD4 
count and type of ART were adjusted for each other.  
b Other type of ARTs: include ARTs composed of TDF-3TC-NVP, ZDV-3TC-NVP or ZDV-3TC-EFV 
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Table 4. Association of baseline CD4 count and type of ART with occurrence of HIV-
related clinical events in asymptomatic HIV infected pregnant women who contributed 682 
person-years 
Exposures Person years of follow-up Number of events  Unadjusted  
HR (95% CI) 
Adjusted a 
HR (95% CI) 
Baseline CD4 (cells/mm3)     
>500  184 2 1 1 
350 to 499  141 3 1.95(0.33-11.65) 2.01 (0.35-12.55) 
< 350  357 19 4.92(1.15-21.12) 4.10 (0.91-18.47) 
Type of ART      
TDF-3TC-EFV 553 14 1 1 
Other ART types b 129 10 3.12(1.39-7.03) 2.28(0.94-5.51) 
 HR: hazard ratio, ART: antiretroviral therapy, TDF-3TC-EFV: a combination of tenofovir, lamivudine and 
efavirenz, 
a The regression analyses were adjusted for age at treatment initiation, gestational age at ART initiation, weight at 
treatment initiation, marital status, level of education, hemoglobin level and treatment adherence. In addition, 
baseline CD4 count and type of ART were adjusted for each other.  
b Other type of ARTs: include ARTs composed of TDF-3TC-NVP, ZDV-3TC-NVP or ZDV-3TC-EFV 
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